The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study by Aksam Yassin (14779204)

“…This was accompanied by an increase in estradiol levels by 14.9 pmol/L (<i>p</i> < 0.0001), and decreases in progesterone (0.2 ng/mL, <i>p</i> < 0.0001), LH (10.4 U/L, <i>p</i> < 0.0001) and FSH (8.4 U/L, <i>p</i> < 0.0001) were demonstrated at 12-years. …”

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polyc... by Thozhukat Sathyapalan (704787)

“…</p><h3>Results</h3><p dir="ltr">There was significant reduction in ASP (156.7 ± 16.2 vs. 124.4 ± 14.8 ng/ml p <0.01), IL-6 (1.48 ± 0.29 vs.0.73 ± 0.34 pg/ml p = 0.01) and MCP-1 (30.4 ± 4.2 vs. 23.0 ± 4.5 pg/ml p = 0.02) after 12 weeks of atorvastatin that was maintained subsequently with 12 weeks treatment with metformin. …”

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 by Stein Emil, Vollset

Get full text
Get full text
Get full text

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 co... by Alize J, Ferrari

Get full text
Get full text
Get full text

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2... by Michael, Brauer

Get full text
Get full text
Get full text

Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults by Nowell H, Phelps

Get full text
Get full text
Get full text